FOOTHILL
RANCH, Calif., May 9, 2022
/PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global
leader in dental lasers, today announced that Kenneth P. Yale, D.D.S., J.D. was newly elected
to its Board of Directors (the "Board"), effective April 28, 2022. Dr. Yale, along with other
recently elected Board members, Drs. Kathleen T. O'Loughlin, Carol Gomez Summerhays, and Martha Somerman, will provide insight and
support the implementation of the Company's business plan, which
has demonstrated significant growth over the past several
quarters.
Dr. Yale is currently on the Board of Visitors at the
University of Maryland School of
Dentistry, and a consultant to the United States Department
of Defense (DOD), a position he has held since March 2020. Previously Dr. Yale held positions as
the Chief Clinical Officer at Delta Dental, Vice President of
Clinical Solutions and Medical Director at Aetna, Chief Executive
at UnitedHealth Group MSO, and Corporate VP of Matria Healthcare
and CorSolutions. He was also Founder and CEO of Advanced Health
Solutions, CEO of Health Solutions Network, and SVP and General
Counsel for EduNeering, an Internet content company. Dr. Yale
also served as Chief of Staff of the White House Office of Science
and Technology and Executive Director of the White House Domestic
Policy Council. Dr. Yale received a D.D.S. in Dentistry from the
University of Maryland and a J.D. in
Law, Science and Medicine from Georgetown
University. Dr. Yale brings to the Board multi-disciplinary
clinical, dental, and legal expertise with deep industry
understanding.
Jonathan T. Lord, M.D., Chairman
of the Board of BIOLASE, commented, "Dr. Yale brings more than 20
years of senior executive experience in entrepreneurial and large
healthcare companies, managing teams facing rapid growth and
change, and creating breakthrough innovations in healthcare
products and services. His extensive dental experience and industry
knowledge complement the diverse makeup of our board, which is now
comprised of a majority of dentists. With the help of their
clinical expertise, our board's newly formed clinical committee is
focused on aligning our research and development efforts to provide
strategic and operational advice regarding current and planned
clinical research and development programs to accelerate the
adoption of lasers as the gold standard of care in dentistry. We
are delighted to welcome Dr. Yale to our board and look forward to
his contributions as we continue to successfully execute our
business plan to achieve our growth objectives."
About BIOLASE
BIOLASE is a medical device company that develops,
manufactures, markets, and sells laser systems in dentistry and
medicine. BIOLASE's products advance the practice of dentistry and
medicine for patients and healthcare professionals. BIOLASE's
proprietary laser products incorporate approximately 301 patented
and 32 patent-pending technologies designed to provide biologically
and clinically superior performance with less pain and faster
recovery times. BIOLASE's innovative products provide cutting-edge
technology at competitive prices to deliver superior results for
dentists and patients. BIOLASE's principal products are
revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical
applications. BIOLASE has sold over 43,300 laser systems
to date in over 80 countries around the world. Laser products under
development address BIOLASE's core dental market and other adjacent
medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase
Express™, and laser dentistry, find BIOLASE online
at www.biolase.com, Facebook at www.facebook.com/biolase,
Twitter at www.twitter.com/biolaseinc, Instagram
at www.instagram.com/waterlase_laserdentistry, and LinkedIn
at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered
trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that
term is defined in the Private Litigation Reform Act of 1995, that
involve significant risks and uncertainties, including statements
regarding the anticipated roll out of new go-to-market sales
strategies, the Company's efforts to achieve its goal of becoming
EBITDA positive. Forward-looking statements can be identified
through the use of words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," "may,"
"will," "should," and variations of these words or similar
expressions. Readers are cautioned not to place undue reliance on
these forward-looking statements, which reflect BIOLASE's current
expectations and speak only as of the date of this release. Actual
results may differ materially from BIOLASE's current expectations
depending upon a number of factors. These factors include,
among others, adverse changes in general economic and market
conditions, competitive factors including but not limited to
pricing pressures and new product introductions, uncertainty of
customer acceptance of new product offerings and market changes,
risks associated with managing the growth of the business, and
those other risks and uncertainties that are described, from
time-to-time, in the "Risk Factors" section of BIOLASE's annual
reports filed on Form 10-K with the Securities and Exchange
Commission. Except as required by law, BIOLASE does not undertake
any responsibility to revise or update any forward-looking
statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biolase-strengthens-its-board-of-directors-with-addition-of-seasoned-healthcare-executive-301542269.html
SOURCE BIOLASE, Inc.